Clinical trials: Treatment-Resistant Major Depressive Disorder
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Treatment-resistant Depression (TRD), Major Depression
Relationship of Peripheral Inflammatory and Neuroprotective Biomarkers With Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression
Treatment-resistant depression (TRD) is a major clinical challenge affecting a substantial proportion of patients with major depressive disorder who do not adequately respond to conventional antidepressant treatments.
- Trial name
- TRD-BIOTMS (NCT07673913)
- Testing
- Intermittent Theta Burst Stimulation (iTBS)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Major Depressive Disorder (MDD)
The Effect of Transcranial Magnetic Stimulation Treatment on Microvasculature Stracture of the Retina and the Choroid
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMS_OCT-A (NCT06708013)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Depression, Major Depressive Disorder
Reward Emotion Learning and Ketamine Study
Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully described.
- Conditions
- Depression, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- RELAKS (NCT04850911)
- Testing
- Ketamine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Major Depressive Disorder, Treatment Resistant Depression
Investigation of the Effects of Repetitive Transcranial Magnetic Stimulation on Cognition in Depression
According to the World Health Organization, MDD is attributed as the leading cause of disability worldwide, leaving 300 million individuals affected.
- Trial name
- NCT03977038
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder, Depression
Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI
The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression.
- Trial name
- NCT03642522
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Major Depressive Disorder, Treatment Resistant Depression
Antidepressant Effects of Nitrous Oxide
To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and…
- Trial name
- NCT05357040
- Testing
- Nitrous oxide gas for inhalation
- Where
- 2 sites in United States, Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Chicago
Major Depressive Disorder
The Antidepressant Advisor (Study 3): fMRI Study to Predict Treatment Response in Patients With Depression
This prospective observational study (ADeSS-Study3) investigates candidate biomarkers prospectively predicting response to antidepressant medications and prognosis in major depressive disorder (MDD).
- Trial name
- ADeSS_S3 (NCT04342299)
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- King's College London
Post-Traumatic Stress Disorders, Major Depressive Disorder
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability.
- Trial name
- NCT04032301
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Depression, Neurofeedback
Neurofeedback In Treatment Resistant Depression
The investigators evaluate the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04078438
- Testing
- neurofeedback augmentation, treatment as usual
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Yeungnam University Hospital
Major Depressive Disorder
Treatment Resistant Geriatric Depression in Primary Care
This study involves collaboration between McLean Hospital, Geriatric Medicine at the Cambridge Health Alliance (CHA) and other sites within the Partners and Harvard Medical School network.
- Trial name
- NCT01392287
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Treatment Resistant Depression
Ketamine Frequency Treatment for Major Depressive Disorder
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range…
- Trial name
- NCT00646087
- Testing
- Ketamine, Ketamine/Saline
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Essentia Health
Major Depressive Disorder, Treatment Resistant Depression
The Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression
Major Depressive Disorder (MDD) is a very common illness that is usually treated with antidepressant medication. Depression can be caused by many things such as childhood experiences, genetics, and changes in the way the body and…
- Trial name
- NCT06163625
- Testing
- Repetitive Transcranial Magnetic Stimulation, Research Interview, Questionnaires, Brain Scan
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Major Depressive Disorder
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP)…
- Trial name
- NCT02134808
- Testing
- Creatine
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Major Depression Moderate, Major Depression Severe
EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in older age patients diagnosed with Major Depressive Episode, Major Depression, and Bipolar Disorder…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07740694
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Treatment-Resistant Major Depressive Disorder
Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)
Clinical trial aimed at evaluating whether a single infusion of tocilizumab, a medication that blocks the action of an inflammatory molecule called interleukin-6 (IL-6), can reduce symptoms of treatment-resistant major depression…
- Trial name
- NCT07052058
- Testing
- Tocilizumab, Normal Saline (0.9% NaCl)
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Late Life Depression, Cognitive Decline
Dopaminergic Dysfunction in Late-Life Depression
Late-Life Depression (LLD), or depression in older adults, often presents with motivational deficits, deficits in performance in cognitive domains including processing speed and executive dysfunction, and mobility impairments.
- Conditions
- Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa
- Trial name
- D3 (NCT04469959)
- Testing
- L-Dopa
- Where
- 2 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center